/VXRT
VXRT Stock - Vaxart, Inc.
Healthcare|BiotechnologyNASDAQ
$0.35-5.41%
$0.02 (-5.41%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.25
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.85
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+471.4%upside
Target: $2.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VXRT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.35 – $0.35
TARGET (TP)$2.00
STOP LOSS$0.32
RISK/REWARD1:55.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.88
52W High$0.98
52W Low$0.26
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $28.70M | $7.38M | $107,000 | $892,000 | $4.05M |
| Gross Profit | $28.70M | $2.88M | $107,000 | $-47,857,000 | $-15,817,000 |
| Gross Margin | 100.0% | 39.0% | 100.0% | -5365.1% | -390.9% |
| Operating Income | $-66,293,000 | $-83,347,000 | $-114,587,000 | $-72,752,000 | $-30,170,000 |
| Net Income | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 | $-32,220,000 |
| Net Margin | -233.3% | -1117.6% | -100708.4% | -7900.2% | -796.3% |
| EPS | $-0.14 | $-0.17 | $-0.22 | $-0.14 | $-0.07 |
Company Overview
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$4
Average Target
↑ 1042.9% Upside
Now
$4
Low
$4
Average
$4
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 15th 2024 | Oppenheimer | Initiation | Outperform | $4 |
Earnings History & Surprises
VXRTBeat Rate
67%
Last 18 quarters
Avg Surprise
+0.8%
EPS vs Estimate
Beats / Misses
12/3
3 met exactly
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.12vs$-0.15
Q2 24
+12.5%
$-0.14vs$-0.16
Q3 24
-237.5%
$-0.09vs$-0.03
Q4 24
+40.0%
$-0.06vs$-0.10
Q1 25
+50.0%
$-0.05vs$-0.10
Q2 25
0.0%
$-0.07vs$-0.07
Q3 25
+22.2%
$-0.07vs$-0.09
Q4 25
+42.9%
$-0.04vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.06 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.07 | $-0.07 | 0.0% | = MET |
Q1 2025 | Mar 20, 2025 | $-0.10 | $-0.05 | +50.0% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.03 | $-0.09 | -237.5% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.16 | $-0.14 | +12.5% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.18 | $-0.11 | +38.9% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.19 | $-0.16 | +15.8% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.19 | $-0.19 | 0.0% | = MET |
Q1 2023 | Mar 15, 2023 | $-0.22 | $-0.18 | +18.2% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.24 | $-0.23 | +4.2% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.17 | $-0.20 | -17.6% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.17 | $-0.17 | 0.0% | = MET |
Q4 2021 | Nov 4, 2021 | $-0.15 | $-0.14 | +6.7% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.14 | $-0.13 | +7.1% | ✓ BEAT |
Latest News
Vaxart, Precigen among biotech gainers after Q3 results
📈 PositiveSeeking Alpha•Nov 14, 2025, 07:06 PM•Also:
Vaxart (OTC: VXRT) Q3 EPS $(0.04) Up From $(0.06) YoY, Sales $72.41M Up From $4.93M YoY
📈 PositiveBenzinga•Nov 13, 2025, 09:07 PM
Dynavax Technologies Collaborates With Vaxart To Develop, Commercialize COVID-19 Vaccines On Vaxart's Platform; Dynavax Will Pay $25M Upfront License Fee, $5M Equity Investment In Vaxart
📈 PositiveBenzinga•Nov 5, 2025, 09:02 PM•Also:
Vaxart Withdraws Its Reverse Stock Split Proposal
📉 NegativeBenzinga•Sep 19, 2025, 12:06 PM
Vaxart's Second-Generation Oral Norovirus Vaccine Shows Up To 25-Fold Increase In Protective Fecal IgA In Phase 1 Trial
📈 PositiveBenzinga•Sep 10, 2025, 09:03 PM
Vaxart Revenue Jumps 520% in Fiscal Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 08:48 PM
Vaxart soars on positive data from new norovirus vaccine trial
📈 PositiveSeeking Alpha•Jun 11, 2025, 02:18 PM
Frequently Asked Questions about VXRT
What is VXRT's current stock price?
Vaxart, Inc. (VXRT) is currently trading at $0.35 per share. The stock has moved -5.41% today.
What is the analyst price target for VXRT?
The average analyst price target for VXRT is $2.00, based on 1 analyst.
What sector is Vaxart, Inc. in?
Vaxart, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VXRT's market cap?
Vaxart, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does VXRT pay dividends?
No, Vaxart, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACRV
Acrivon Therapeutics, Inc. Common Stock
$2.16
Mkt Cap: $0.1B
CAMP
CAMP4 Therapeutics Corporation
$6.38
Mkt Cap: $0.1B
CBUS
Cibus, Inc.
$1.71
Mkt Cap: $0.1B
FBIO
Fortress Biotech, Inc.
$3.54
Mkt Cap: $0.1B
IMUX
Immunic, Inc.
$0.57
Mkt Cap: $0.1B
PMVP
PMV Pharmaceuticals, Inc.
$1.24
Mkt Cap: $0.1B
RLMD
Relmada Therapeutics, Inc.
$4.35
Mkt Cap: $0.3B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
TCRX
TScan Therapeutics, Inc.
$0.90
Mkt Cap: $0.1B
UNCY
Unicycive Therapeutics, Inc.
$5.56
Mkt Cap: $0.1B
Explore stocks similar to VXRT for comparison